Given that we have previously shown an immune modulating effect of the α7nAChR agonist AR-R17779 in primary microglia cultures [14] and that AR-R17779 has not been tested in in vivo models of brain injury, we set out to investigate the potential in vivo effect of AR-R17779 to decrease neuroinflammation and counteract stroke-induced brain damage using the tMCAO model. This evidence concerns the gene CHRNA7 and Stroke.